tradingkey.logo

tradingkey.logo
怜玢


Immatics NV

IMTX
りォッチリストに远加
6.390USD
-0.130-1.99%
終倀 11-13 16:00ET
972.75M時䟡総額
損倱額盎近12ヶ月PER

Immatics NVに぀いお 䌁業名

Immatics NV is a clinical-stage biopharmaceutical company that is based in the Netherlands. The Company is focused on the discovery and development of T-Cell eceptors with the goal of enabling a robust and specific T-Cell response against these targets. The Company develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). Its wholly owned pipeline comprises of eight therapeutic programs, of which four are in clinical trials, including IMA201 (MAGEA4/8), IMA202 (MAGEA1) and ACTolog IMA 101 (Multi-target pilot trial) for solid cancers and IMA203 (PRAME) for hematological and solid cancers, as well as four are in preclinical development, including IMA204 (COL6A3) and IMA401 (Cancer testis antigen) for solid cancers, and ACTallo IMA301 (Cancer testis antigen) and IMA402 (Cancer testis antigen) for hematological and solid cancers.

Immatics NV プロフィヌル


䌁業コヌドIMTX
䌚瀟名Immatics NV
䞊堎日Jul 02, 2020
最高経営責任者「CEO」Singh (Harpreet)
埓業員数297
蚌刞皮類Ordinary Share
決算期末Jul 02
本瀟所圚地Paul Ehrlich-Strasse 15
郜垂TUEBINGEN
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜Germany
郵䟿番号72076
電話番号4970715397700
りェブサむトhttps://immatics.com/
䌁業コヌドIMTX
䞊堎日Jul 02, 2020
最高経営責任者「CEO」Singh (Harpreet)

Immatics NVの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Steffen Walter, Ph.D.
Dr. Steffen Walter, Ph.D.
Chief Operating Officer
Chief Operating Officer
502.83K
+24.29%
Dr. Mathias Hothum, Ph.D.
Dr. Mathias Hothum, Ph.D.
Non-Executive Director
Non-Executive Director
394.52K
+10.14%
Mr. Jordan Silverstein
Mr. Jordan Silverstein
Head of Strategy
Head of Strategy
384.98K
+26.63%
Mr. Edward Sturchio, J.D.
Mr. Edward Sturchio, J.D.
General Counsel
General Counsel
300.63K
+33.47%
Mr. Arnd Christ
Mr. Arnd Christ
Chief Financial Officer
Chief Financial Officer
276.84K
+38.63%
Mr. Michael G. (Mike) Atieh
Mr. Michael G. (Mike) Atieh
Non-Executive Independent Director
Non-Executive Independent Director
130.00K
+32.93%
Mr. Paul Rutherford Carter
Mr. Paul Rutherford Carter
Non-Executive Independent Director
Non-Executive Independent Director
130.00K
+32.93%
Dr. Alise S. Reicin, M.D.
Dr. Alise S. Reicin, M.D.
Temporary Non-Executive Director
Temporary Non-Executive Director
30.00K
+66.67%
Dr. Carsten J. Reinhardt, M.D., Ph.D.
Dr. Carsten J. Reinhardt, M.D., Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Ms. Amie Krause
Ms. Amie Krause
Chief People Officer
Chief People Officer
--
--
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Steffen Walter, Ph.D.
Dr. Steffen Walter, Ph.D.
Chief Operating Officer
Chief Operating Officer
502.83K
+24.29%
Dr. Mathias Hothum, Ph.D.
Dr. Mathias Hothum, Ph.D.
Non-Executive Director
Non-Executive Director
394.52K
+10.14%
Mr. Jordan Silverstein
Mr. Jordan Silverstein
Head of Strategy
Head of Strategy
384.98K
+26.63%
Mr. Edward Sturchio, J.D.
Mr. Edward Sturchio, J.D.
General Counsel
General Counsel
300.63K
+33.47%
Mr. Arnd Christ
Mr. Arnd Christ
Chief Financial Officer
Chief Financial Officer
276.84K
+38.63%
Mr. Michael G. (Mike) Atieh
Mr. Michael G. (Mike) Atieh
Non-Executive Independent Director
Non-Executive Independent Director
130.00K
+32.93%

よくある質問

Immatics NVの䞊䜍5名の株䞻は誰ですか


Immatics NVの䞊䜍5名の株䞻は以䞋のずおりです。Dr. Steffen Walter, Ph.D.

Immatics NVIMTXの株匏を保有しおいる機関の数はいく぀ですか


2026Q1時点で、Immatics NVの株匏を保有しおいる機関は191瀟あり、保有株匏の総垂堎䟡倀は玄101.84Mで、党䜓の75.94%を占めおいたす。2025Q4ず比范しお、機関の持ち株は-17425391.00増加しおいたす。
tradingkey.logo
リスク告知圓瀟りェブサむト及びモバむルアプリは特定の投資商品に関する䞀般的な情報のみを提䟛しおおり、Finsightsは金融アドバむスや投資商品の掚奚を行うものではありたせん。本情報の提䟛をもっおFinsightsが投資助蚀を行っおいるず解釈されるこずはありたせん。
投資商品には元本割れを含む重倧なリスクが䌎い、党おの投資家に適するものではありたせん。なお、過去の運甚実瞟は将来の成果を保蚌するものではありたせん。
Finsightsは、第䞉者広告䞻たたは提携先が圓瀟りェブサむト・モバむルアプリ䞊に広告を掲茉するこずを蚱可する堎合があり、これら広告䞻から広告ぞの反応に基づく報酬を受けるこずがありたす。
© 著䜜暩: FINSIGHTS MEDIA PTE. LTD. 無断耇写・転茉を犁じたす。